Quoin net loss widens 45.32% to $5.4 million in Q2 FY26

• Quoin Pharmaceuticals posted a Q2 net loss of $5.37 million, widening from $3.7 million a year earlier.
• R&D expense climbed to $3.63 million from $2.05 million; G&A expense rose to $1.85 million from $1.74 million.
• Cash, cash equivalents, and marketable securities totaled $10.8 million at June 30; management expects funding into 2027.
• FDA conditionally cleared QYLEKI as QRX003’s proposed brand name for Netherton syndrome; Quoin also cited a positive pediatric compassionate-use update.
• FDA cleared an IND for QRX003 in Peeling Skin Syndrome, enabling a Phase 2/3 study planned to start in the second half of 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Quoin Pharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608140830PRIMZONEFULLFEED9809893) on August 14, 2026, and is solely responsible for the information contained therein.